Drug profile · INN
metaraminol bitartrate
METARAMINOL BITARTRATE
metaraminol bitartrate (METARAMINOL BITARTRATE) is a adrenergic receptor alpha-1 agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — metaraminol bitartrate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
metaraminol bitartrate (METARAMINOL BITARTRATE) is a adrenergic receptor alpha-1 agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-1 agonist
Primary target: Adrenergic receptor alpha-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is metaraminol bitartrate?
metaraminol bitartrate (METARAMINOL BITARTRATE) is a adrenergic receptor alpha-1 agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for metaraminol bitartrate?
METARAMINOL BITARTRATE is a marketed brand name for metaraminol bitartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of metaraminol bitartrate?
metaraminol bitartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.